Literature DB >> 8200469

Pregnancy and paroxysmal nocturnal hemoglobinuria.

J Bais1, M Pel, A von dem Borne, H van der Lelie.   

Abstract

A patient is described who developed symptoms of paroxysmal nocturnal hemoglobinuria (PNH) in her first pregnancy. This was uneventful except for a spontaneous preterm delivery. The second pregnancy was complicated by severe anemia and a hemolytic crisis with Budd-Chiari syndrome at 31 weeks' amenorrhoea. Delivery was again preterm and was the result of induced labour after premature rupture of membranes at 34 weeks. Literature shows a high maternal mortality among PNH patients (5.8%). The most common cause of death is liver vein thrombosis (Budd-Chiari syndrome). Fetal wastage (30%) and prematurity rate (16%) are also high. Recommendations for follow-up and therapy are given such as anticoagulation therapy, platelets and washed erythocytes transfusions, screening for Budd-Chiari syndrome and infections.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8200469     DOI: 10.1016/0028-2243(94)90121-x

Source DB:  PubMed          Journal:  Eur J Obstet Gynecol Reprod Biol        ISSN: 0301-2115            Impact factor:   2.435


  10 in total

1.  Paroxysmal nocturnal hemoglobinuria and pregnancy before the eculizumab era: the French experience.

Authors:  Sophie de Guibert; Régis Peffault de Latour; Nathalie Varoqueaux; Hélène Labussière; Bernard Rio; Dominique Jaulmes; Jean-Richard Eveillard; Stéphanie Dulucq; Anne-Marie Stoppa; Didier Bouscary; François Girodon; Bernard Bonnotte; Djamila Laskri; Gérard Socié; Thierry Lamy
Journal:  Haematologica       Date:  2011-05-23       Impact factor: 9.941

Review 2.  The complement system and adverse pregnancy outcomes.

Authors:  Jean F Regal; Jeffrey S Gilbert; Richard M Burwick
Journal:  Mol Immunol       Date:  2015-03-21       Impact factor: 4.407

3.  Pregnancy outcomes in women receiving eculizumab for the management of paroxysmal nocturnal haemoglobinuria.

Authors:  James E Manning; Rachel M Anderson; Anita Hill; Doaa Zeidan; Etienne Ciantar
Journal:  Obstet Med       Date:  2021-06-20

Review 4.  Paroxysmal nocturnal haemoglobinuria.

Authors:  Anita Hill; Amy E DeZern; Taroh Kinoshita; Robert A Brodsky
Journal:  Nat Rev Dis Primers       Date:  2017-05-18       Impact factor: 52.329

Review 5.  Successful anticoagulant therapy for two pregnant PNH patients, and prospects for the eculizumab era.

Authors:  Yasuyoshi Morita; Jun-ichi Nishimura; Takahiro Shimada; Hirokazu Tanaka; Kentaro Serizawa; Yasuhiro Taniguchi; Mitsuhiro Tsuritani; Yuzuru Kanakura; Itaru Matsumura
Journal:  Int J Hematol       Date:  2013-03-02       Impact factor: 2.490

6.  Pregnancy with Paroxysmal Nocturnal Hemoglobinuria: A Case Series with Review of the Literature.

Authors:  Yara Mohammad Al-Dosari; Hazza Al-Zahrani; Fahad Al-Mohareb; Shahrukh Hashmi
Journal:  Saudi J Med Med Sci       Date:  2021-04-29

7.  Successful pregnancy outcome in paroxysmal nocturnal hemoglobinuria (PNH) following escalated eculizumab dosing to control breakthrough hemolysis.

Authors:  Ruby Sharma; Alla Keyzner; Johnson Liu; Thomas Bradley; Steven L Allen
Journal:  Leuk Res Rep       Date:  2015-05-16

Review 8.  Eculizumab in the management of paroxysmal nocturnal hemoglobinuria: patient selection and special considerations.

Authors:  Fatimah Al-Ani; Ian Chin-Yee; Alejandro Lazo-Langner
Journal:  Ther Clin Risk Manag       Date:  2016-08-01       Impact factor: 2.423

9.  Preoperative administration of eculizumab to prevent surgery-triggered hemolysis during cesarean section with paroxysmal nocturnal hemoglobinuria.

Authors:  Dongping Li; Liangcheng Wang; Isao Horiuchi; Shun-Ichi Kimura; Kenro Chikazawa; Azusa Kimura; Shigetane Sasaki; Tomoyuki Kuwata; Kenjiro Takagi
Journal:  Clin Case Rep       Date:  2018-07-25

Review 10.  How we('ll) treat paroxysmal nocturnal haemoglobinuria: diving into the future.

Authors:  Antonio Maria Risitano; Régis Peffault de Latour
Journal:  Br J Haematol       Date:  2021-08-05       Impact factor: 8.615

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.